


Life Sciences

2017: Recognized both globally and nationally for its leading life sciences practice, WilmerHale has more than four decades of experience representing biotechnology, pharmaceutical and medical device companies at all stages of growth, as well as venture capitalists and investment banks. We have represented life sciences clients in venture financings, public offerings, mergers and acquisitions, and licensing agreements and collaborations; protected their innovations through patent prosecution and portfolio development; defended their interests in enterprise-critical patent litigation; and navigated regulatory issues vital to their success. The following is a selection of our recent life sciences transactions.

Counsel of Choice to Life Sciences Innovators

SERVING INDUSTRY LEADERS IN BIOTECHNOLOGY, PHARMACEUTICALS, MEDICAL DEVICES AND BEYOND



Mergers and Acquisitions/Strategic Alliances and Collaborations

 Sale of global portfolio of hemostasis products to Mallinckrodt \$410,000,000 (including contingent payments) February 2016	 Acquisition of Viventia Bio \$35,400,000 (including contingent payments) September 2016	 Acquisition by Hologic \$1,650,000,000 March 2017	 Acquisition of Alfa Aesar research chemicals business of Johnson Matthey £256,000,000 September 2015
---	---	--	---

 Metabolic immuno-oncology collaboration with Celgene	 Collaboration with Janssen to develop DART [®] molecule product	 Duchenne muscular dystrophy collaboration with Sarepta	 Acquisition of Shire's mRNA therapy platform	 Ocular gene editing product collaboration with Allergan
--	--	--	--	---

Venture Capital Financings

 \$130,000,000 Second Round June 2016	 \$90,000,000 Second Round December 2015	 \$40,000,000 Late Stage January 2016	 \$68,000,000 Third Round April 2016	 \$55,000,000 First Round July 2016
 \$55,000,000 Late Stage December 2015	 \$51,200,000 Late Stage May 2016	 \$23,500,000 First Round November 2016	 \$23,100,000 Third Round June 2016	

Initial Public Offerings and Follow-on Offerings

 Public Offering of Common Stock \$181,125,000 Counsel to Issuer June 2016	 Public Offering of 3.25% Convertible Senior Notes \$460,000,000 Counsel to Issuer July 2016	 Public Offering of Common Stock \$172,500,000 Counsel to Issuer September 2016	 Initial Public Offering of Common Stock \$57,500,000 Counsel to Issuer July 2016
---	---	--	--

 Initial Public Offering of Common Stock \$108,560,000 Counsel to Issuer February 2016	 Public Offering of Common Stock \$11,500,000 Counsel to Issuer September 2016	 Issuer Tender Offer for Senior Notes \$3,000,000,000 Counsel to Offerors April 2016	 Public Offerings of 2.950% and 3.000% Senior Notes \$2,200,000,000 Counsel to Issuer April and September 2016	 Public Offering of Common Stock \$50,000,000 Counsel to Issuer August 2016
 Public Offering of Common Stock \$138,000,000 Counsel to Issuer January 2016	 Public Offering of Common Stock \$52,450,000 Counsel to Issuer October 2016	 Public Offering of Common Stock \$50,000,000 Counsel to Issuer November 2016	 Rights Offering of Common Shares, including Common Shares represented by American Depositary Shares \$25,000,000 Counsel to Issuer December 2016	 Public Offerings of Common Stock \$65,000,000 Counsel to Issuer November 2016 and January 2017

 Public Offering of 0.750% and 1.375% Senior Notes €1,600,000,000 Counsel to Issuer September 2016	 Public Offering of Common Stock \$57,960,000 Counsel to Underwriters January 2017	 Public Offering of Common Stock \$50,000,000 Counsel to Issuer May 2016	 Initial Public Offering of Common Stock \$11,339,000 Counsel to Issuer May 2016
---	---	---	---



Mixed Sources
 Product group from well-managed forests, controlled sources and recycled wood or fiber
www.fsc.org Cert no. BV-COC-070904
 © 1996 Forest Stewardship Council

17_0297 KW 4/17 2000

WilmerHale recognizes its corporate responsibility to environmental stewardship.

Connect with us   

wilmerhale.com

Wilmer Cutler Pickering Hale and Dorr LLP is a Delaware limited liability partnership. WilmerHale principal law offices: 60 State Street, Boston, Massachusetts 02109, +1 617 526 6000; 1875 Pennsylvania Avenue, NW, Washington, DC 20006, +1 202 663 6000. Our United Kingdom office is operated under a separate Delaware limited liability partnership of solicitors and registered foreign lawyers authorized and regulated by the Solicitors Regulation Authority (SRA No. 287488). Our professional rules can be found at www.sra.org.uk/solicitors/code-of-conduct.page. A list of partners and their professional qualifications is available for inspection at our UK office. In Beijing, we are registered to operate as a Foreign Law Firm Representative Office. This material is for general informational purposes only and does not represent our advice as to any particular set of facts; nor does it represent any undertaking to keep recipients advised of all legal developments. Prior results do not guarantee a similar outcome. © 2017 Wilmer Cutler Pickering Hale and Dorr LLP